MICHELLE A FANALE to Cytarabine
This is a "connection" page, showing publications MICHELLE A FANALE has written about Cytarabine.
Connection Strength
0.087
-
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018 06 15; 124(12):2561-2569.
Score: 0.024
-
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2018 08; 24(8):1602-1609.
Score: 0.024
-
Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2015 Nov; 171(4):509-16.
Score: 0.020
-
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec; 163(5):611-20.
Score: 0.018